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Precis:  In our experience, indeterminate diagnoses (FLUS+FN+SM) accounted for the majority 
(60%) of preoperative FNAs for incidental microcarcinoma (size ≤0.5 cm) when compared to 
27% for those of non-incidental microcarcinoma (size >0.5 cm and ≤1 cm) (p<0.05, chi-square 
test). 
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ABSTRACT: 
INTRODUCTION: 
Widespread use of ultrasound allows for detection of smaller thyroid nodules and preoperative 
evaluation with fine-needle aspiration (FNA). Both incidental and non-incidental 
microcarcinoma can be found, leading to uncertainty with clinical management.   
MATERIALS AND METHODS: 
A retrospective analysis of thyroid FNAs performed at our institution was conducted for the 5-
year period from 2010 to 2014. Aspirates were categorized using the Bethesda System for 
Reporting Thyroid Cytopathology. Cytologic diagnoses were then correlated with final 
histopathology. Among samples with malignancy on surgical resection, nodules were stratified 
by size. 
RESULTS: 
A total of 2531 thyroid FNAs were identified. 587 samples had histologic correlation, and 259 
malignancies were reported. They were separated into nodules >1 cm (n=144, 56%) and ≤1 cm 
(n=115, 44%). Microcarcinoma was further subdivided into incidental (size ≤0.5 cm, n=55, 48%) 
and non-incidental (size >0.5 cm and ≤1 cm, n=60, 52%). The preoperative cytologic diagnoses 
for incidental microcarcinoma were: benign (B, n=11, 20%), follicular lesion of undetermined 
significance (FLUS, n=15, 27%), follicular neoplasm (FN, n=11, 20%), suspicious for 
malignancy (SM, n=7, 13%), malignant (M, n=8, 15%), and non-diagnostic (ND, n=3, 5%). The 
FNA categories for non-incidental microcarcinoma were: B (n=13, 22%), FLUS (n=3, 5%), FN 
(n=3, 5%), SM (n=10, 17%), M (n=29, 48%) and ND (n=2, 3%). 
CONCLUSIONS:   
Incidental microcarcinoma is not an uncommon entity, making up 21% (55/259) of malignant 
nodules on thyroidectomy. Indeterminate diagnoses (FLUS+FN+SM) accounted for the majority 
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(60%) of preoperative FNAs for incidental microcarcinoma when compared to 27% for those of 
non-incidental microcarcinoma (p<0.05, chi-square test). 
 
KEYWORDS:  thyroid; FNA; cytology; the Bethesda System; microcarcinoma 
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MANUSCRIPT TEXT: 
INTRODUCTION: 
Thyroid cancer is the most common malignancy of the endocrine system, and the incidence has 
dramatically increased in recent years. The majority of cases consist of papillary thyroid 
carcinoma (PTC), making up more than 80% of histologic diagnoses.1-3 A paramount study with 
the Surveillance, Epidemiology, and End Results (SEER) data exhibited a nearly threefold 
increase in PTC from 1973 to 2009.1,4 The bulk of this increase was shown to be associated with 
an upsurge in cancers of smaller size. Microcarcinoma, defined as measuring ≤1 cm by the 
World Health Organization, comprised 49% of the increase in incidence.1,5 
 
It is unclear whether the rising incidence is a true epidemic of disease or reflects the enhanced 
detection of thyroid nodules with advanced imaging techniques.1,6 Many nodules are discovered 
during the use of head and neck imaging for unrelated symptoms. Widespread use of ultrasound, 
computed tomography, magnetic resonance imaging, and positron emission tomography allows 
for detection of smaller thyroid nodules. Ultrasound imaging can detect nodules as small as 0.2 
cm in dimension, but the clinical significance of these findings is highly debated.1,7  
 
Microcarcinoma is generally thought to have an indolent nature, presenting as an ancillary 
finding at the time of histologic examination. Foci of papillary thyroid microcarcinoma have 
been reported in up to 22% of surgical thyroid specimens and up to 36% of autopsy series.6,8-11 
However, its biologic behavior can be variable with associated morbidity and mortality. Some 
patients have local lymph node metastases or distant metastases at the time of diagnosis or 
during years of follow-up.7,12-13 Other authors have even reported cancer-related deaths.14 
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A pioneer study in 1987 described a higher rate of lymph node metastasis in patients with thyroid 
microcarcinoma >0.5 cm when compared to microcarcinoma ≤0.5 cm.15 Since that publication, 
many research groups have examined the significance of various clinicopathologic risk factors 
with an established size cutoff of 0.5 cm.16-19 One study corroborated the finding of an increased 
incidence of lymph node metastasis in patients with microcarcinoma >0.5 cm, supporting the 
importance of this size distinction.16 A second publication went further to report the cutoff of 
>0.5 cm to be an independent predictor of subclinical central lymph node metastasis.19 Another 
study found a significant difference in extrathyroidal extension in patients with microcarcinoma 
>0.5 cm.17 There is potential value in using 0.5 cm as a size parameter when analyzing 
microcarcinoma. 
 
Standard of care for thyroid cancer and lymph node involvement is total thyroidectomy with 
central lymph node dissection.19 However, the rise in both incidental and non-incidental 
microcarcinoma has generated controversy surrounding optimal management. There is little 
epidemiologic data on the broad spectrum of disease characteristics and long-term prognosis of 
microcarcinoma.20 Recommendations for clinical management range from observation alone to 
total thyroidectomy with lymph node dissection and radioactive iodine.2,8,12,20-22 
 
Ultrasound-guided fine-needle aspiration (FNA) is a fundamental component to the preoperative 
evaluation of thyroid nodules. It is a safe and minimally invasive modality, separating nodules 
into well-defined diagnostic tiers to steer appropriate patient care.9 Nevertheless, there is little 
known about the relationship between microcarcinoma and cytologic categories on FNA. 
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Microcarcinoma has a clear impact on the increasing incidence of thyroid cancer. We sought to 
investigate the correlation between microcarcinoma and preoperative cytology to facilitate 
communication with clinicians. 
 
MATERIALS AND METHODS: 
This study was approved by the Institutional Review Board of Indiana University. A 
retrospective analysis of thyroid FNAs performed at our institution was conducted for the 5-year 
period from 2010 to 2014. All aspirates were categorized into six groups using the Bethesda 
System for Reporting Thyroid Cytopathology (TBSRTC).23  
 
A computer search of the anatomic pathology archives and the electronic medical record was 
performed to document the histologic results of patients who underwent surgery. The cytologic 
diagnoses were then correlated with the final histopathology. In cases with multiple nodules, 
preoperative FNAs were matched with corresponding histology based on the location in the 
thyroid gland when that information was available. Identification of biopsy related changes in 
direct association with nodules was beyond the scope of this retrospective study.  
 
Among the samples with malignancy on surgical resection, nodules were stratified by size. 
According to the criteria outlined by the World Health Organization, thyroid microcarcinoma 
was designated as 1 cm or less in greatest dimension.5 To further classify microcarcinoma, there 
are different definitions for incidental and non-incidental microcarcinoma in the literature. For 
our statistical analysis, we used size as the deciding factor. Previous studies highlight tumor size 
as an important clinicopathologic factor, but various size cutoffs have been applied. There are 
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reports of higher rates of lymph node metastases and extrathyroidal extension in cases >0.5 
cm.15-19 It provides support to our designation of 0.5 cm as a reasonable size cutoff. In our study, 
malignant nodules ≤0.5 cm were classified as incidental microcarcinoma. In contrast, nodules 
>0.5 cm and ≤1 cm were delineated as non-incidental microcarcinoma.  
 
In order to address the recent revision in nomenclature, the cases previously diagnosed as 
encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) were reassessed. Two 
cases originated at an outside institution, and these slides were not available for review. The 
reported diagnoses were maintained for our analysis. All other slides were examined by a board-
certified pathologist (HHW). The prevailing diagnostic criteria for noninvasive follicular thyroid 
neoplasm with papillary-like nuclear features (NIFTP) were applied as necessary.24  
 
A chi-square test using an online calculator was performed to compare the rate of indeterminate 
FNA diagnoses between the group of incidental microcarcinoma and non-incidental 
microcarcinoma. The result was found to be significant at p<0.05 
(http://www.socscistatistics.com/tests/chisquare/Default.aspx). 
 
RESULTS: 
A total of 2531 thyroid FNA samples were identified, and 587 FNAs had surgical follow-up with 
histologic correlation. 259 malignant thyroid nodules were found in 220 patients (167 females, 
53 males) with an age range of 16 to 88 years. They were associated with preoperative cytologic 
diagnoses as follows: benign (B, n=27, 10%), follicular lesion of undetermined significance 
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(FLUS, n=40, 15%), follicular neoplasm (FN, n=23, 9%), suspicious for malignancy (SM, n=36, 
14%), malignant (M, n=126, 49%), and non-diagnostic (ND, n=7, 3%) (Table 1). 
 
Malignancies were separated by size into nodules >1 cm (n=144, 56%) and microcarcinomas ≤1 
cm (n=115, 44%). With the nodules >1 cm, final histopathology showed evidence of sizes 
ranging from 1.1 to 13 cm in greatest dimension (Table 1). Among cases of thyroid 
microcarcinoma, the nodules were 0.1 to 1.0 cm in size. 
 
With the initial separation by size, malignant nodules >1 cm correlated with the following 
preoperative cytologic diagnoses: B (n=3, 2%), FLUS (n=22, 15%), FN (n=9, 6%), SM (n=19, 
13%), M (n=89, 62%), and ND (n=2, 1%) (Table 1).  
  
Microcarcinoma was further subdivided into incidental microcarcinoma (size ≤0.5 cm, n=55, 
48%) and non-incidental microcarcinoma (size >0.5 cm and ≤1 cm, n=60, 52%) (Table 1). The 
corresponding preoperative cytologic diagnoses for incidental microcarcinoma were: B (n=11, 
20%), FLUS (n=15, 27%), FN (n=11, 20%), SM (n=7, 13%), M (n=8, 15%), and ND (n=3, 5%) 
(Table 1). The cytologic diagnoses for non-incidental microcarcinoma were: B (n=13, 22%), 
FLUS (n=3, 5%), FN (n=3, 5%), SM (n=10, 17%), M (n=29, 48%) and ND (n=2, 3%) (Table 1). 
 
According to the new paradigm shift, reclassification of cases revealed 10 nodules >1 cm 
(10/144, 7%) met the diagnostic criteria for NIFTP. Malignancies >1 cm subsequently included 
classic papillary thyroid carcinoma (PTC, 91/134, 68%), invasive follicular variant of papillary 
thyroid carcinoma (FVPTC, 20/134, 15%), follicular carcinoma (11/134, 8%), anaplastic 
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carcinoma (8/134, 6%), and metastatic renal cell carcinoma (4/134, 3%). These nodules 
correlated with the following cytologic diagnoses: B (n=1, 1%), FLUS (n=17, 13%), FN (n=8, 
6%), SM (n=18, 13%), M (n=89, 66%), and ND (n=1, 1%) (Table 2).  
 
With the non-incidental micronodules (>0.5 cm and ≤1 cm), 4 cases could be categorized as 
NIFTP (4/60, 7%) (Table 3). After exclusion of NIFTP, non-incidental microcarcinoma 
comprised PTC (38/56, 68%), FC (2/56, 4%), FVPTC (14/56, 25%), tall cell variant of papillary 
thyroid carcinoma (TCV, 1/56, 2%), and medullary carcinoma (MTC, 1/56, 2%) (Table 3). They 
corresponded with the following FNA diagnoses: B (n=12, 21%), FLUS (n=2, 4%), FN (3, 
n=5%), SM (n=9, 16%), M (n=29, 52%), and ND (n=1, 2%) (Table 2).  
 
Incidental microcarcinoma ≤0.5 cm consisted of PTC (n=32, 58%), FVPTC (n=20, 36%), and 
MTC (n=3, 6%) (Table 4). In the category of FVPTC, a total of 10 cases were partially 
encapsulated (10/20, 50%), and 7 had no capsule (7/20, 35%). None of these 17 cases showed 
evidence of lymphovascular invasion or extrathyroidal extension; however, they are too small to 
be classified as NIFTP. One case displayed minimal capsular invasion. Furthermore, one case 
demonstrated a concurrent lymph node metastasis, and one case had lymphovascular invasion. 
Of note, the case with lymph node metastasis had a clinical history of classic papillary thyroid 
carcinoma on the contralateral side, status post hemithyroidectomy. Also, the case with 
lymphovascular invasion had a synchronous papillary thyroid carcinoma on the opposite side. 
The presence of a metastasis cannot be completely excluded in these two scenarios.  Lastly, one 
case originated at an outside institution, and the slides were not available for review. The 
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reported diagnosis was maintained for our analysis. Due to limitations in this evaluation, the 
overall number of NIFTP is likely higher than reported. 
 
DISCUSSION:   
Among prognostic factors related to thyroid carcinoma, the most controversial aspect is the 
tumor size.  Most cases of microcarcinoma have an indolent clinical course, and some clinicians 
believe nodules ≤1 cm should not be biopsied.7 However, there is a subset of patients with 
aggressive disease who present with bulky lymph node involvement and/or distant 
metastases.7,12-14 
 
Fine-needle aspiration is indispensable to the evaluation of thyroid nodules, and it facilitates risk 
stratification of patients. Little data has been published on the relationship between 
microcarcinoma and the preoperative classification according to TBSRTC. We sought to 
evaluate the cytologic diagnoses of thyroid FNAs and correlate it with the final histopathology of 
microcarcinoma.  
 
While the majority of malignant nodules had a size >1 cm (144/259, 56%), the presence of 
microcarcinoma was also evident in our population (115/259, 44%) (Table 1). Incidental thyroid 
microcarcinoma with size ≤0.5 cm is not an uncommon entity. It accounted for 21% (55/259) of 
malignant nodules that were discovered on follow-up thyroidectomy. It was similar in value to 
non-incidental microcarcinoma (size >0.5 cm and ≤1 cm) (23%, 60/259) (Table 1). 
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Not surprisingly, most malignant nodules >1 cm were associated with the cytologic category of 
malignant (89/144, 62%) (Table 1). Nevertheless, this did not hold true with microcarcinoma in 
our population. Indeterminate categories (FLUS+FN+SM) accounted for the majority (60%) of 
preoperative FNA diagnoses for incidental microcarcinoma when compared to 27% for those of 
non-incidental microcarcinoma (p<0.05, chi-square test) (Table 1).  
 
This data was compiled and analyzed before the recent publication supporting a paradigm shift to 
revise the nomenclature used in thyroid pathology. After gathering our original data, a second 
tier of analysis was performed to address the new terminology of NIFTP.24 The inclusion criteria 
were created based on evaluation of tumors ≥1 cm, yet there was no minimum size established 
for future application of the diagnosis.25 To thoroughly explore the issue, we examined tumors of 
all sizes with the diagnosis of EFVPTC in the final pathology report.  
 
The task of reclassifying the malignancies generated only a slight adjustment in the statistical 
results. Of the original 204 malignant nodules that were >0.5 cm, review of the cases of 
EFVPTC revealed only 14 cases (7%) met the criteria to now be defined as NIFTP.24 In our 
population, most of these cases were >1 cm in size (10/14). The remaining cases were non-
incidental micronodules with size >0.5 cm and ≤1 cm (4/14) (Table 3). None of the incidental 
microcarcinomas necessitated a new classification (Table 4). 
 
Several recent studies on the characteristics of thyroid microcarcinoma and aspects associated 
with aggressive disease found size to be an important risk factor. In one retrospective cohort, 
microcarcinoma ≥0.8 cm was shown to be associated with neck lymph node involvement and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12
distant metastases at presentation and recurrence of disease at follow-up.11 Another study 
uncovered increased risk for central lymph node metastases in tumors ≥0.6 cm.26 Lastly, long-
term follow-up in Japan found patients with tumor size of 0.1-0.5 cm had an improved 
recurrence-free survival rate 35 years after surgery when compared to patients with tumor size of 
0.6-1.0 cm.20 
 
The exact size predictive of aggressive disease in microcarcinoma appears to slightly vary with 
the study population. Our distinction of non-incidental microcarcinoma (>0.5 cm and ≤1 cm) and 
incidental microcarcinoma (≤0.5 cm) is in accordance with the separation points used in other 
analyses.15-20,26 After exclusion of NIFTP, the indeterminate categories (FLUS+FN+SM) still 
accounted for the majority (60%) of preoperative FNA diagnoses for incidental microcarcinoma 
when compared to 25% for those of non-incidental microcarcinoma (p<0.05, chi-square test) 
(Table 2).  
 
These results can presumably be attributed to a sampling issue inherent to the procedure and not 
solely an interpretation error. The cytologic diagnoses were rendered by multiple different board-
certified pathologists and often with use of intradepartmental consensus. With our designation of 
≤0.5 cm as incidental microcarcinoma, it is reasonable to surmise that many of these were indeed 
incidental findings and too small to be adequately sampled by fine-needle aspiration. A sample 
composed of atypical cells admixed with normal follicular cells would result in an indeterminate 
diagnosis on FNA. Among the cases with a cytologic diagnosis of either FLUS or FN (26 cases, 
47%), all of the cases showed benign nodules (adenomas, hyperplastic nodules, and lymphocytic 
thyroiditis) adjacent to the incidental microcarcinoma in the resection specimens. However, in 8 
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cases (15%), size ranging from 0.3 cm to 0.5 cm, there were sufficient cellular changes for us to 
render a definite malignant diagnosis.  
 
Earlier studies indicated that microcarcinoma was an entity mostly discovered in thyroid glands 
removed for benign disease or at the time of autopsy. Recent trends in cancer surveillance and 
advanced diagnostic techniques have contributed to a shift in size distribution toward smaller 
tumors.1,4,27 Due to the uncertain behavior of microcarcinoma, the use of FNA on thyroid nodules 
≤1 cm has been a frequent topic of debate.10 The 2015 American Thyroid Association guidelines 
discourage using FNA to evaluate subcentimeter thyroid nodules in patients without evidence of 
extrathyroidal extension or a sonographically suspicious lymph node.28 However, current 
recommendations justify the use of FNA to assess nodules ≤1 cm with worrisome features such 
as hypoechogenicity, irregular margins, and microcalcifications on ultrasound imaging.9-10 
 
Regardless of size, thyroid nodules with suspicious findings can be subjected to preoperative 
evaluation with fine-needle aspiration. Our analysis highlights the incidence of microcarcinoma 
and its correlation with each FNA category. Although the cytology smears may not be definitive, 
this should not deter clinicians from using fine-needle aspiration to assess smaller nodules. 
Imaging characteristics, patient demographics, and clinical risk factors all play a role in 
management. Knowing that microcarcinoma can contribute to an indeterminate diagnosis creates 
an indispensable platform for clinicians to discuss treatment options with patients. When an 
indeterminate diagnosis is rendered on FNA, microcarcinoma is a legitimate possibility. Active 
surveillance is a viable approach for patients with papillary microcarcinoma, but we propose that 
surgical resection such as lobectomy may be a better option for patients who are good surgical 
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candidates. Understanding the prominence of microcarcinoma associated with each cytologic 
diagnosis is instrumental to guide optimal clinical management.  
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TABLES: 
 
Table 1. FNA Diagnosis and Malignant Nodules on Surgical Follow-Up 
FNA Diagnosis ≤0.5 cm >0.5 cm and ≤1 cm >1 cm (1.1-13 cm) 
B (n=27, 10%) 11 (20%) 13 (22%) 3 (2%) 
FLUS (n=40, 15%) 15 (27%) 3 (5%) 22 (15%) 
FN (n=23, 9%) 11 (20%) 3 (5%) 9 (6%) 
SM (n=36, 14%) 7 (13%) 10 (17%) 19 (13%) 
M (n=126, 49%) 8 (15%) 29 (48%) 89 (62%) 
ND (n=7, 3%) 3 (5%) 2 (3%) 2 (1%) 
Total (n=259) 55 60 144 
B=Benign; FLUS=Follicular lesion of undetermined significance; FN=Follicular neoplasm; 
SM=Suspicious for malignancy; M=Malignant; ND=Non-diagnostic 
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Table 2. FNA Diagnosis and Malignant Nodules after Exclusion of NIFTP 
FNA Diagnosis >0.5 cm and ≤1 cm >1 cm (1.1-13 cm) 
B (n=13, 7%) 12 (21%) 1 (1%) 
FLUS (n=19, 10%) 2 (4%) 17 (13%) 
FN (n=11, 6%) 3 (5%) 8 (6%) 
SM (n=27, 14%) 9 (16%) 18 (13%) 
M (n=118, 62%) 29 (52%) 89 (66%) 
ND (n=2, 1%) 1 (2%) 1 (1%) 
Total (n=190) 56 134 
NIFTP= Noninvasive follicular thyroid neoplasm with papillary-like nuclear features 
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Table 3. Histologic Types of Non-incidental Micronodules (>0.5 cm and ≤1 cm) 
FNA Diagnosis PTC FC FVPTC NIFTP Other 
B (n=13) 6 1 4 1 1 (MTC) 
FLUS (n=3) 1  1 1  
FN (n=3) 1 1 1   
SM (n=10) 6  3 1  
M (n=29) 23  5  1 (TCV) 
ND (n=2) 1   1  
Total (n=60) 38 2 14 4 2 
PTC=Papillary thyroid carcinoma; FC=Follicular carcinoma; FVPTC=Follicular variant of 
papillary thyroid carcinoma; MTC=Medullary thyroid carcinoma; TCV=Tall cell variant of 
papillary thyroid carcinoma 
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Table 4. Histologic Types of Incidental Micronodules (≤0.5 cm) 
FNA Diagnosis PTC FVPTC Other (MTC) 
B (n=11) 6 4 1 
FLUS (n=15) 7 8  
FN (n=11) 7 4  
SM (n=7) 4 2 1 
M (n=8) 6 1 1 
ND (n=3) 2 1  
Total (n=55) 32 20 3 
 
 
 
 
 
 
